Suppr超能文献

接受维持性泼尼松免疫抑制治疗的肾移植受者肾移植术后胰腺的类固醇撤减

Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression.

作者信息

Fridell Jonathan A, Agarwal Avinash, Powelson John A, Goggins William C, Milgrom Martin, Pescovitz Mark D, Tector A Joseph

机构信息

Department of Surgery, Indiana University School of Medicine, Indianapolis, 46202, USA.

出版信息

Transplantation. 2006 Aug 15;82(3):389-92. doi: 10.1097/01.tp.0000228904.01482.88.

Abstract

UNLABELLED

Steroid withdrawal from patients taking prednisone for their renal allograft at the time of reinduction of immunosuppression for subsequent pancreas after kidney (PAK) transplantation has not been explored. Our expectation was that lymphocyte depletion, in conjunction with an augmentation of immunosuppression at the time of pancreas transplantation would protect the recipient from rejection of the renal allograft when chronic maintenance steroids are withdrawn.

METHODS

Pancreas transplantation was performed using systemic venous drainage and enteric exocrine drainage. Regardless of preoperative immunosuppression, all patients received induction with antithymocyte globulin, a brief taper of intravenous solumedrol over four to five days, maintenance therapy with tacrolimus and sirolimus and either resumption of chronic maintenance steroids or complete withdrawal of steroids.

RESULTS

A total of 30 PAK transplants were performed in 29 recipients and divided into two groups: continuation of chronic steroids (n = 10) or steroid-free (n = 19). One pancreas allograft was lost and there was a single mortality in the steroid free group. There was no significant difference in renal function or incidence of infections.

CONCLUSION

Steroids can be safely withdrawn following pancreas after kidney transplantation for recipients already on maintenance prednisone in the setting of rabbit antithymocyte globulin induction and tacrolimus and sirolimus maintenance immunosuppression.

摘要

未标记

对于接受肾移植后服用泼尼松的患者,在进行后续肾胰联合移植(PAK)并重新诱导免疫抑制时停用类固醇的情况尚未进行研究。我们的预期是,在胰腺移植时淋巴细胞清除结合免疫抑制增强,在停用慢性维持类固醇时可保护受者免受肾移植排斥。

方法

采用全身静脉引流和肠道外分泌引流进行胰腺移植。无论术前免疫抑制情况如何,所有患者均接受抗胸腺细胞球蛋白诱导、在四到五天内短暂递减静脉注射甲泼尼龙、使用他克莫司和西罗莫司进行维持治疗,以及恢复慢性维持类固醇或完全停用类固醇。

结果

共对29例受者进行了30例PAK移植,分为两组:继续使用慢性类固醇(n = 10)或无类固醇组(n = 19)。有一个胰腺移植失败,无类固醇组有一例死亡。肾功能或感染发生率无显著差异。

结论

对于已在接受泼尼松维持治疗的受者,在兔抗胸腺细胞球蛋白诱导以及他克莫司和西罗莫司维持免疫抑制的情况下,肾胰联合移植后可安全停用类固醇。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验